CASI PHARMAC. NEW O.N.
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipe… Read more
Market Cap & Net Worth: CASI PHARMAC. NEW O.N. (ENM)
CASI PHARMAC. NEW O.N. (F:ENM) has a market capitalization of $14.98K (€14.60K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #44357 globally and #7264 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CASI PHARMAC. NEW O.N.'s stock price €1.54 by its total outstanding shares 9478 (9.48K).
CASI PHARMAC. NEW O.N. Market Cap History: 2015 to 2026
CASI PHARMAC. NEW O.N.'s market capitalization history from 2015 to 2026. Data shows growth from $8.47K to $14.98K (2.49% CAGR).
CASI PHARMAC. NEW O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CASI PHARMAC. NEW O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ENM by Market Capitalization
Companies near CASI PHARMAC. NEW O.N. in the global market cap rankings as of March 19, 2026.
Key companies related to CASI PHARMAC. NEW O.N. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CASI PHARMAC. NEW O.N. Historical Marketcap From 2015 to 2026
Between 2015 and today, CASI PHARMAC. NEW O.N.'s market cap moved from $8.47K to $ 14.98K, with a yearly change of 2.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €14.98K | 0.00% |
| 2025 | €14.98K | 0.00% |
| 2024 | €14.98K | 0.00% |
| 2023 | €14.98K | -3.75% |
| 2022 | €15.57K | +126.95% |
| 2021 | €6.86K | -68.24% |
| 2020 | €21.60K | -21.28% |
| 2019 | €27.44K | -24.60% |
| 2018 | €36.39K | +45.53% |
| 2017 | €25.00K | +135.13% |
| 2016 | €10.63K | +25.49% |
| 2015 | €8.47K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CASI PHARMAC. NEW O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.98K USD |
| MoneyControl | $14.98K USD |
| MarketWatch | $14.98K USD |
| marketcap.company | $14.98K USD |
| Reuters | $14.98K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.